EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Reclassification of a spindle cell sarcoma after identification of a TFG‐ROS1 fusion: A case demonstrating the clinical benefit of next‐generation sequencing in sarcoma

John J Lim, Eleanor Y Chen iD, Stephanie K Schaub, Michael J Wagner iD

Molecular Genetics & Genomic Medicine · 2024-04 · 12 (4)

DOI: 10.1002/mgg3.2423 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Molecular Genetics & Genomic Medicine, online erschienen am 15.04.2024. Verfasst von John J Lim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Protein-Tyrosine Kinases, Sarcoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inflammatory myofibroblastic tumors (IMTs) are rare mesenchymal soft tissue sarcomas that often present diagnostic challenges due to their wide and varied morphology. A subset of IMTs have fusions involving ALK or ROS1. The role of next‐generation sequencing (NGS) for classification of unselected sarcomas remains controversial. Methods and Results We report a case of a metastatic sarcoma in a 34‐year‐old female originally diagnosed as an unclassified spindle cell sarcoma with myofibroblastic differentiation and later reclassified as IMT after NGS revealed a TFG‐ROS1 rearrangement. Histologically, the neoplasm had spindle cell morphology with a lobulated to focally infiltrative growth pattern with scant inflammatory cell infiltrate. Immunohistochemistry demonstrated focal desmin and variable smooth muscle actin staining but was negative for SOX10, S100, and CD34. Fluorescence in situ hybridization was negative for USP6 or ALK gene rearrangements. NGS revealed a TFG‐ROS1 rearrangement and the patient was treated with crizotinib with clinical benefit.

Conclusions

We discuss the role of NGS as well as its potential benefit in patients with unresectable, ALK ‐negative metastatic disease. Considering this case and previous literature, we support the use of NGS for patients requiring systemic treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Tyrosine KinasesSarcomaFemaleHumansAdultAnaplastic Lymphoma KinaseIn Situ Hybridization, FluorescenceProto-Oncogene ProteinsHigh-Throughput Nucleotide SequencingUbiquitin ThiolesteraseVesicular Transport Proteins

Stichwörter der Autor:innen

NGSROS1crizotinibinflammatory myofibroblastic tumor (IMT)sarcoma

Substanzen

Protein-Tyrosine KinasesAnaplastic Lymphoma KinaseProto-Oncogene ProteinsUSP6 protein, humanUbiquitin ThiolesteraseROS1 protein, humanTFG protein, humanVesicular Transport Proteins

Autor:innen und Institutionen

  • Division of Medical Oncology, University of Washington, Seattle, Washington, USA.
  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
  • Division of Radiation Oncology, University of Washington, Seattle, Washington, USA.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.

ORCID-Profile: Eleanor Y Chen, Michael J Wagner

Zitieren

APA

Lim, J. J., Chen, E. Y., Schaub, S. K., & Wagner, M. J. (2024). Reclassification of a spindle cell sarcoma after identification of a TFG‐ROS1 fusion: A case demonstrating the clinical benefit of next‐generation sequencing in sarcoma. Molecular Genetics & Genomic Medicine, 12(4). https://doi.org/10.1002/mgg3.2423

Vancouver

Lim JJ, Chen EY, Schaub SK, Wagner MJ. Reclassification of a spindle cell sarcoma after identification of a TFG‐ROS1 fusion: A case demonstrating the clinical benefit of next‐generation sequencing in sarcoma. Molecular Genetics & Genomic Medicine. 2024;12(4). doi:10.1002/mgg3.2423

BibTeX
@article{Lim2024,
  author = {Lim, John J and Chen, Eleanor Y and Schaub, Stephanie K and Wagner, Michael J},
  title = {Reclassification of a spindle cell sarcoma after identification of a TFG‐ROS1 fusion: A case demonstrating the clinical benefit of next‐generation sequencing in sarcoma},
  journal = {Molecular Genetics & Genomic Medicine},
  year = {2024},
  volume = {12},
  number = {4},
  doi = {10.1002/mgg3.2423}
}
Kostenlos starten →